Acquired resistance to erlotinib in EGFR mutation-positive lung adenocarcinoma among Hispanics (CLICaP)
Lung cancer harboring epidermal growth factor receptor (EGFR) mutations and treated with EGFR tyrosine kinase inhibitors (TKIs) all eventually develop acquired resistance to the treatment, with half of the patients developing EGFR T790M resistance mutations. The purpose of this study was to assess h...
- Autores:
-
Cardona-Mendoza, Andrés Felipe
Arrieta, Oscar
Zapata, Martín Ignacio
Rojas Puentes, Leonardo
Wills, Beatriz
Reguart, Noemí
Karachaliou, Niki
Carranza Isaza, Hernán
Vargas Báez, Carlos Alberto
Otero, Jorge
Archila, Pilar
Martín, Claudio
Corrales, Luis
Cuello, Mauricio
Ortiz, Carlos
Pino, Luis E.
Rosell, Rafael
Zatarain-Barrón, Zyanya Lucia
- Tipo de recurso:
- https://purl.org/coar/resource_type/c_6501
- Fecha de publicación:
- 2017
- Institución:
- Universidad El Bosque
- Repositorio:
- Repositorio U. El Bosque
- Idioma:
- eng
- OAI Identifier:
- oai:repositorio.unbosque.edu.co:20.500.12495/4626
- Palabra clave:
- Clorhidrato de erlotinib
Adenocarcinoma del pulmón
Genes erbB-1
- Rights
- License
- Acceso abierto